A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache

Table 2

The secondary efficacy measures between pretreatment and posttreatment stages.

Variables	Pretreatment		1 value	Posttreatment		2 value
	DSC ()	Placebo ()		DSC ()	Placebo ()
Headache days (m)	22.65 ± 5.39	23.32 ± 5.21	0.30	10.66 ± 7.73	15.3 ± 8.57	<0.01
Headache duration (d)	9.4 ± 8	9.8 ± 8.14	0.73	4.62 ± 5.92	6.25 ± 6.7	<0.01
Analgesic usage	5.58 ± 2.99	5.09 ± 2.71	0.15	2.47 ± 2.17	3.36 ± 2.88	<0.01
Severity of pain (VAS)	5.54 ± 2.1	5.56 ± 2.41	0.91	2.5 ± 1.89	3.42 ± 2.37	<0.01
Disability	2.18 ± 1.41	2.36 ± 1.7	0.55	0.69 ± 1.06	1.27 ± 1.55	<0.01